MedTrace Logo

Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials

NCT00828919 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2024-12-03

Study results available
· View outcomes & findings →

Summary

To allow continuation of axitinib (AG 013736) treatment to patients experiencing clinical benefit in a closing axitinib trial

Conditions

Interventions

DRUG

axitinib

BID oral tablets. dose of axitinib (AG 013736) will be the same as they were taking in the previous trial

DRUG

crizotinib

BID oral Capsules. Dose of crizotinib will be the same taken in previous axitinib trial.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-07
Primary Completion
2023-08-14
Completion
2023-08-14

Countries

  • United States
  • Czechia
  • France
  • Germany
  • Hungary
  • Italy
  • Japan
  • Russia
  • South Korea
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00828919 on ClinicalTrials.gov